FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892325513> ?p ?o ?g. }

• W2892325513 endingPage "e559" @default.
• W2892325513 startingPage "e553" @default.
• W2892325513 abstract "Background Increased D-dimer concentrations are associated with poor cardiovascular and other clinical outcomes in people with treated HIV infection. Proteinase activated receptor-1 (PAR-1) is activated by thrombin and overexpressed by immune cells from HIV-infected people. We aimed to study the efficacy of vorapaxar, a licensed inhibitor of PAR-1, in reducing HIV-associated hypercoagulation and inflammation. Methods This was a multicentre, double-blind, randomised, placebo-controlled trial done in seven hospital clinics in Australia and the USA. Eligible participants were HIV-infected, aviraemic, were receiving stable antiretroviral therapy, and had D-dimer concentrations greater than 200 ng/mL. We randomly assigned participants (1:1) using computer-generated block lists of size two to receive vorapaxar (2·5 mg orally daily) or matched placebo for 12 weeks. Participants were reviewed and had a blood sample taken at weeks 1, 4, 8, and 12 during treatment, and at a final visit at week 18. The primary endpoint was treatment group difference in changes from baseline D-dimer concentrations after 8–12 weeks of treatment, and was assessed in the modified intention-to-treat population (participants who had at least one dose of study drug or one follow-up visit). This trial is registered with ClinicalTrials.gov, number NCT02394730, and is closed to new participants. Findings Between Oct 21, 2015, and July 14, 2017, 65 eligible patients were randomly assigned to the placebo group (n=31) or vorapaxar group (n=34). One patient from the vorapaxar group did not receive any study drug, and the modified intention-to-treat population was comprised of 33 patients. D-dimer concentrations after 8–12 weeks of treatment did not differ significantly between groups (difference −0·02 log10 ng/mL, 95% CI −0·10 to 0·05; p=0·56). Vorapaxar treatment was safe and well tolerated in this cohort. There were 161 adverse events (n=84 in the placebo group and n=77 in the vorapaxar group), and five protocol-defined serious adverse events that required hospital admission for more than 24 h (n=2 in the placebo group and n=3 in the vorapaxar group). One patient ceased taking vorapaxar because of an adverse event. There were 25 bleeding events, 23 of which were mild, one was moderate, and one was severe. Interpretation Vorapaxar had no effect on D-dimer concentrations in HIV-infected patients receiving stable antiretroviral therapy but at risk of poor outcomes. Alternative approaches are needed to reduce hypercoagulation, inflammation, and adverse long-term outcomes in patients with treated HIV infection. Funding Australian National Health and Medical Research Council, US National Cancer Institute, National Institutes of Health. Increased D-dimer concentrations are associated with poor cardiovascular and other clinical outcomes in people with treated HIV infection. Proteinase activated receptor-1 (PAR-1) is activated by thrombin and overexpressed by immune cells from HIV-infected people. We aimed to study the efficacy of vorapaxar, a licensed inhibitor of PAR-1, in reducing HIV-associated hypercoagulation and inflammation. This was a multicentre, double-blind, randomised, placebo-controlled trial done in seven hospital clinics in Australia and the USA. Eligible participants were HIV-infected, aviraemic, were receiving stable antiretroviral therapy, and had D-dimer concentrations greater than 200 ng/mL. We randomly assigned participants (1:1) using computer-generated block lists of size two to receive vorapaxar (2·5 mg orally daily) or matched placebo for 12 weeks. Participants were reviewed and had a blood sample taken at weeks 1, 4, 8, and 12 during treatment, and at a final visit at week 18. The primary endpoint was treatment group difference in changes from baseline D-dimer concentrations after 8–12 weeks of treatment, and was assessed in the modified intention-to-treat population (participants who had at least one dose of study drug or one follow-up visit). This trial is registered with ClinicalTrials.gov, number NCT02394730, and is closed to new participants. Between Oct 21, 2015, and July 14, 2017, 65 eligible patients were randomly assigned to the placebo group (n=31) or vorapaxar group (n=34). One patient from the vorapaxar group did not receive any study drug, and the modified intention-to-treat population was comprised of 33 patients. D-dimer concentrations after 8–12 weeks of treatment did not differ significantly between groups (difference −0·02 log10 ng/mL, 95% CI −0·10 to 0·05; p=0·56). Vorapaxar treatment was safe and well tolerated in this cohort. There were 161 adverse events (n=84 in the placebo group and n=77 in the vorapaxar group), and five protocol-defined serious adverse events that required hospital admission for more than 24 h (n=2 in the placebo group and n=3 in the vorapaxar group). One patient ceased taking vorapaxar because of an adverse event. There were 25 bleeding events, 23 of which were mild, one was moderate, and one was severe. Vorapaxar had no effect on D-dimer concentrations in HIV-infected patients receiving stable antiretroviral therapy but at risk of poor outcomes. Alternative approaches are needed to reduce hypercoagulation, inflammation, and adverse long-term outcomes in patients with treated HIV infection." @default.
• W2892325513 created "2018-09-27" @default.
• W2892325513 creator A5023462845 @default.
• W2892325513 creator A5030905646 @default.
• W2892325513 creator A5032592545 @default.
• W2892325513 creator A5033467980 @default.
• W2892325513 creator A5040307768 @default.
• W2892325513 creator A5041469251 @default.
• W2892325513 creator A5049234296 @default.
• W2892325513 creator A5054025307 @default.
• W2892325513 creator A5060263230 @default.
• W2892325513 creator A5079993549 @default.
• W2892325513 date "2018-10-01" @default.
• W2892325513 modified "2023-10-18" @default.
• W2892325513 title "Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial" @default.
• W2892325513 cites W1502027120 @default.
• W2892325513 cites W1549306192 @default.
• W2892325513 cites W1988789324 @default.
• W2892325513 cites W2033330877 @default.
• W2892325513 cites W2050125360 @default.
• W2892325513 cites W2056954848 @default.
• W2892325513 cites W2093888975 @default.
• W2892325513 cites W2121850733 @default.
• W2892325513 cites W2123354892 @default.
• W2892325513 cites W2127517680 @default.
• W2892325513 cites W2134322421 @default.
• W2892325513 cites W2141813332 @default.
• W2892325513 cites W2142021807 @default.
• W2892325513 cites W2148092884 @default.
• W2892325513 cites W2151562155 @default.
• W2892325513 cites W2153136696 @default.
• W2892325513 cites W2167709851 @default.
• W2892325513 cites W2336908092 @default.
• W2892325513 cites W2392201426 @default.
• W2892325513 cites W263709140 @default.
• W2892325513 cites W2974799256 @default.
• W2892325513 doi "https://doi.org/10.1016/s2352-3018(18)30214-5" @default.
• W2892325513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30257802" @default.
• W2892325513 hasPublicationYear "2018" @default.
• W2892325513 type Work @default.
• W2892325513 sameAs 2892325513 @default.
• W2892325513 citedByCount "17" @default.
• W2892325513 countsByYear W28923255132020 @default.
• W2892325513 countsByYear W28923255132021 @default.
• W2892325513 countsByYear W28923255132022 @default.
• W2892325513 countsByYear W28923255132023 @default.
• W2892325513 crossrefType "journal-article" @default.
• W2892325513 hasAuthorship W2892325513A5023462845 @default.
• W2892325513 hasAuthorship W2892325513A5030905646 @default.
• W2892325513 hasAuthorship W2892325513A5032592545 @default.
• W2892325513 hasAuthorship W2892325513A5033467980 @default.
• W2892325513 hasAuthorship W2892325513A5040307768 @default.
• W2892325513 hasAuthorship W2892325513A5041469251 @default.
• W2892325513 hasAuthorship W2892325513A5049234296 @default.
• W2892325513 hasAuthorship W2892325513A5054025307 @default.
• W2892325513 hasAuthorship W2892325513A5060263230 @default.
• W2892325513 hasAuthorship W2892325513A5079993549 @default.
• W2892325513 hasBestOaLocation W28923255131 @default.
• W2892325513 hasConcept C126322002 @default.
• W2892325513 hasConcept C141071460 @default.
• W2892325513 hasConcept C142724271 @default.
• W2892325513 hasConcept C168563851 @default.
• W2892325513 hasConcept C202953159 @default.
• W2892325513 hasConcept C203092338 @default.
• W2892325513 hasConcept C204787440 @default.
• W2892325513 hasConcept C27081682 @default.
• W2892325513 hasConcept C2908647359 @default.
• W2892325513 hasConcept C535046627 @default.
• W2892325513 hasConcept C71924100 @default.
• W2892325513 hasConcept C99454951 @default.
• W2892325513 hasConceptScore W2892325513C126322002 @default.
• W2892325513 hasConceptScore W2892325513C141071460 @default.
• W2892325513 hasConceptScore W2892325513C142724271 @default.
• W2892325513 hasConceptScore W2892325513C168563851 @default.
• W2892325513 hasConceptScore W2892325513C202953159 @default.
• W2892325513 hasConceptScore W2892325513C203092338 @default.
• W2892325513 hasConceptScore W2892325513C204787440 @default.
• W2892325513 hasConceptScore W2892325513C27081682 @default.
• W2892325513 hasConceptScore W2892325513C2908647359 @default.
• W2892325513 hasConceptScore W2892325513C535046627 @default.
• W2892325513 hasConceptScore W2892325513C71924100 @default.
• W2892325513 hasConceptScore W2892325513C99454951 @default.
• W2892325513 hasFunder F4320332161 @default.
• W2892325513 hasFunder F4320334705 @default.
• W2892325513 hasFunder F4320337351 @default.
• W2892325513 hasIssue "10" @default.
• W2892325513 hasLocation W28923255131 @default.
• W2892325513 hasLocation W28923255132 @default.
• W2892325513 hasLocation W28923255133 @default.
• W2892325513 hasLocation W28923255134 @default.
• W2892325513 hasOpenAccess W2892325513 @default.
• W2892325513 hasPrimaryLocation W28923255131 @default.
• W2892325513 hasRelatedWork W2890098371 @default.
• W2892325513 hasRelatedWork W2959603226 @default.
• W2892325513 hasRelatedWork W2980596691 @default.
• W2892325513 hasRelatedWork W3106862589 @default.
• W2892325513 hasRelatedWork W3186042544 @default.
• W2892325513 hasRelatedWork W3195806474 @default.

• next